Terns Pharmaceuticals, Inc. (TERN) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 10 Buy, 6 Hold.
The consensus price target is $55.67 (low: $35.00, high: $70.00), representing an upside of 5.7% from the current price $52.68.
Analysts estimate Earnings Per Share (EPS) of $-1.19 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.12 vs est $-1.19 (beat +6.3%). 2025: actual $-1.03 vs est $-1.07 (beat +3.3%). Analyst accuracy: 95%.
TERN Stock — 12-Month Price Forecast
$55.67
▲ +5.68% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Terns Pharmaceuticals, Inc., the average price target is $55.67, with a high forecast of $70.00, and a low forecast of $35.00.
The average price target represents a +5.68% change from the last price of $52.68.
Highest Price Target
$70.00
Average Price Target
$55.67
Lowest Price Target
$35.00
TERN Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Terns Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — TERN
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.12
vs Est –$1.19
▲ 6.7% off
2025
Actual –$1.03
vs Est –$1.07
▲ 3.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TERN
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
